Orphazyme Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Denmark
Total Funding:$263.3M
Industry:Biotech
Founded:2009
Lead Investor(s):N/A

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Orphazyme's estimated annual revenue is currently $24.8M per year.
  • Orphazyme's estimated revenue per employee is $155,000
  • Orphazyme's total funding is $263.3M.

Employee Data

  • Orphazyme has 160 Employees.
  • Orphazyme grew their employee count by 45% last year.
  • Orphazyme currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Genmab
$98.4M63537%N/AN/A
Gubra
$27.7M17934%N/AN/A
Unibio
$8.4M548%N/AN/A
Orphazyme
$24.8M16045%N/AN/A
Ascendis Pharma...
$63.1M40745%N/AN/A
Missing a competitor? Contribute!?
Submit

Danish biotech company listed on Nasdaq Copenhagen (TICKER: ORPHA.CO), with a late-stage drug pipeline, developing new treatment options for orphan protein-misfolding diseases, including sporadic Inclusion Body Myositis (sIBM), Amyotrophic Lateral Sclerosis (ALS), Niemann Pick Type C (NPC), and Gaucher. Anticipated completion of three potential registration studies by end 2020, with the first potential marketing authorization in 2020.

keywords:N/A

160

Number of Employees

$24.8M

Revenue (est)

1

Current Jobs

45%

Employee Growth %

$263.3M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Orphazyme News

08/27/2019 - Worldwide Clinical Trials Works with Orphazyme to Complete ...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing ...

08/27/2019 - Orphazyme announces Interim Report First Half 2019

Copenhagen, Denmark, August 28, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing ...

08/28/2019 - Orphazyme Partnership to Run Through Extension of Phase 3 ...

Orphazyme announced that it and Worldwide Clinical Trials will continue their collaboration through the long-term extension of a Phase 3 study ...